Document:

Exhibit 10.1

      

      

      FIRST AMENDMENT TO

      MYOVANT SCIENCES LTD.

      2020 INDUCEMENT PLAN

       

      This First Amendment amends the 2020 Inducement Plan (the “Plan”) of Myovant Sciences Ltd. (the “Company”).  Unless otherwise specifically defined herein, each capitalized
        term used herein shall have the meaning afforded such term under the Plan.

       

      W I T N E S S E T H:

      

      

      WHEREAS, at the meeting on March 22, 2022, the Compensation Committee of the Board of Directors of the Company determined it to be in
        the best interests of the Company to amend the Plan to increase the number of shares of stock authorized for issuance thereunder to 2,000,000 shares of stock, pursuant to its authority under Section 2(b)(vi) of the Plan:

       

      NOW, THEREFORE, be it resolved that the Plan is hereby amended as follows:

       

      
        	 	
                1.

              	
                Share Reserve.  Section 3(a)(i) of
                  the Plan shall be amended as follows:

              

         

        

      

      
        	 	
                a.

              	
                The number set forth in Section 3(a)(i) (viz., 1,000,000) is hereby deleted and replaced with the number 2,000,000.

              

         

        

      

      
        	 	
                2.

              	
                Date of Amendment.  To record the adoption of this
                  Amendment to the Plan by the Compensation Committee as of March 22, 2022, the Company has caused its authorized officer to execute the same.

              

      

      

      

      	 	
              MYOVANT SCIENCES LTD.

            
	 	 
	 	
              By:

            	
              /s/ David Marek

            
	 	
              Name:

            	
              David Marek

            
	 	
              Its:

            	
              Principal Executive OfficerExhibit
10.1

CONVERTIBLE
NOTE

	$50,000	San
    Diego, California	March
    21, 2022

 

FOR
VALUE RECEIVED, the undersigned, Neuropathix, Inc., a Delaware corporation (“Debtor”), promises to pay to the order
of [INVESTOR], a [ ], or order (“Holder”), at the corporate offices of Holder, or such other place as Holder
may designate in writing, the principal amount of Fifty Thousand and 00/100 Dollars ($50,000), together with interest on the unpaid
principal balance from time to time outstanding, computed on the basis of a three hundred sixty (360) day year and compounded on a yearly
basis at a rate equal to Three Percent (3%) per annum (the “Interest Rate”).

1.       Payment
of Principal and Interest. From the date of this Convertible Note (the “Note” or “Convertible Note”),
interest shall be payable annually beginning on March 21, 2023 until the maturity date of March 21, 2032, at which time all principal
and interest accrued thereon shall be due and payable in United States currency.

2.       Prepayment.
Debtor shall not be permitted to prepay this Note, either in whole or in part, without the express written consent of Holder, which consent
Holder may withhold in its sole and absolute discretion.

3.       Conversion
of Note.

(a)       Any
Holder of this Note has the right, at the Holder's option, at any time prior to payment in full of the principal balance of this Note,
to convert this Note, in whole or in part, into fully paid and nonassessable shares of Debtor’s common stock ("Common Stock").
The number of shares of Common Stock into which this Note may be converted ("Conversion Shares") shall be determined
by dividing the aggregate principal amount being tendered for conversion including interest accrued thereon (unless Holder elects to
have the interest paid in cash) by the Conversion Price in effect at the time of such conversion. The Conversion Price shall be equal
to the lesser of $0.01 or 70% of the average of the two lowest closing prices of Debtor's
common stock in the ten (10) trading days prior to any particular conversion.

Notwithstanding
the foregoing, Holder shall not be permitted to convert the Note, or portion thereof, if such conversion would result in beneficial ownership
by Holder and its affiliates of more than 4.9% of the Debtor’s outstanding Common Stock as of the date of conversion.

(b)       If
Holder desires to exercise its conversion rights under this Note it may do so by delivering a conversion notice in similar form and substance
as the conversion notice attached hereto as “Attachment 1” at the Debtor’s principal corporate office.

(c)       No
fractional shares shall be issued upon conversion. The amount of shares to be issued upon conversion shall be rounded to the nearest
whole share amount.

(d)
As promptly as practicable after the conversion of this Note, the Debtor at its expense will issue and deliver to Holder of this Note
a certificate or certificates for the number of shares of Common Stock issuable upon such conversion.

4.       Conversion
Price Adjustments.

(a)       In
case at any time the Common Stock outstanding shall be combined into a lesser number of shares, whether by reclassification or reduction
of capital stock, and whether referred to as a “reverse split” or otherwise (a “Share Reduction Event”),
then the Conversion Price shall be proportionately increased by multiplying the Conversion Price immediately preceding a Share Reduction
Event by the sum of (i) the number of shares of Common Stock outstanding immediately prior to a Share Reduction Event divided by (ii)
the number of shares of Common Stock outstanding immediately following such Share Reduction Event.

(b)       
In case at any time any Common Stock shall be issued, or be deemed to have been issued, as a dividend on outstanding Common Stock or
shall be issued upon subdivision, reclassification, recapitalization, whether referred to as a “stock split” or otherwise
(a “Share Increase Event”), then the Conversion Price shall be proportionately decreased by multiplying the Conversion
Price immediately preceding a Share Increase Event by the sum of (i) the number of shares of Common Stock outstanding immediately prior
to a Share Increase Event divided by (ii) the number of shares of Common Stock outstanding immediately following such Share Increase
Event.

5.       Event
of Default. Each of the following shall constitute an Event of Default under this Note:

(a)
       Debtor fails to make any payment when due on this Note or is in default on any other of its
indebtedness that is evidenced by a promissory note (whether convertible or non-convertible) and either Debtor has not received a waiver
of such default or the time to cure such default has lapsed.

(b)       Upon
any assignment by Debtor for the benefit of creditors, or filing by or against Debtor of a petition in bankruptcy, or adjudication of
Debtor as bankrupt or insolvent, or filing by or against Debtor of any petition or answer seeking for Debtor any reorganization, arrangement,
composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation, or filing
any answer admitting or failing to deny the material allegations of a petition filed against it for any such relief, or seeking or consenting
to or acquiescing in the appointment of any trustee, receiver or liquidator of itself or of all or any substantial part of its properties,
or its directors or stockholders taking any action looking to its dissolution or liquidation.

6.       Holder's
Rights. Upon an Event of Default, Holder may declare the entire unpaid principal balance on this Convertible Note together with interest
on any unpaid balance immediately due, without notice, and then Debtor will pay that amount.

If
any Event of Default occurs, neither the failure of Holder to promptly exercise its right to declare the outstanding principal of and
accrued and unpaid interest on this Convertible Note to be immediately due and payable, nor the failure of Holder to exercise any other
right or remedy that it may have for default, nor the acceptance by Holder of late payments, nor the failure of Holder to demand strict
performance of any obligation of Debtor hereunder, shall constitute a waiver of any such rights while such default continues, nor a waiver
of such rights in connection with any future default on the part of Debtor. Furthermore, acceptance by Holder of partial payments following
due acceleration of the indebtedness evidenced hereby shall not constitute a waiver by Holder of the acceleration of such indebtedness

7.       Sale,
Assignment or Transfer of Note. The Holder of this Convertible Note may sell, assign, transfer, pledge or hypothecate this Note at
any time in Holder’s sole and absolute discretion.

8.       Maximum
Rate. All agreements which either are now or which shall become agreements between Debtor and Holder are expressly limited so that
in no contingency or event whatever, whether by reason of deferment or advancement of the indebtedness represented by this Convertible
Note, acceleration of the maturity date of this Convertible Note, or otherwise, shall the amount paid or agreed to be paid to Holder
for the use, forbearance or detention of the indebtedness evidenced by this Convertible Note exceed the maximum amount of interest permissible
under applicable law. If at any time, from any circumstance whatsoever, fulfillment of any provision of this Convertible Note or any
other agreement between Debtor and Holder shall result in or involve payments or performance which would exceed the maximum legal interest
rate, then ipso facto, the obligation to be fulfilled shall be reduced so as not to exceed such maximum legal interest rate.

9.       Waiver.
No delay or omission on the part of any holder hereof in exercising any right or option herein given to such holder shall impair such
right or option to be considered as a waiver thereof or acquiescence in any default hereunder. Debtor hereby waives any applicable statute
of limitations, presentment, demand for payment, protest and notice of dishonor.

10.       Attorney’s
Fees. In the event of any dispute, action, or other proceeding brought by either party against the other under this Convertible Note,
the prevailing party shall be entitled to recover all costs and expenses incurred in connection with such dispute, action, or other proceeding,
including, without limitation, the fees and costs of its attorneys, whether or not such dispute, action, or other proceeding proceeds
to formal resolution or judgment.

11.       Cumulative.
Holder's rights and remedies under this Convertible Note and applicable law shall be cumulative and not in the alternative.

12.       Governing
Law and Venue. This Convertible Note is and shall be governed by and construed and enforced in accordance with the laws of the State
of California without application of conflict of laws principles. Sole and proper venue and jurisdiction for any dispute arising out
of or relating to this Convertible Note shall be San Diego County Superior Court in San Diego, California. 

13.       Successors.
The provisions of this Convertible Note shall inure to the benefit of Holder's successors and assigns, and are binding on Debtor's successors.

14.       Time
of Essence. Time is of the essence under this Convertible Note.

15.       Severability.
Should any one or more of the provisions of this Note be determined to be illegal or unenforceable, such provision(s) shall (i) be modified
to the minimum extent necessary to render it valid and enforceable, or (ii) if it cannot be so modified, be deemed not to be a part of
this Note and shall not affect the validity or enforceability of the remaining provisions.

[Signature
Page Follows]

    	 	1	 

     

    

IN
WITNESS WHEREOF the parties have entered into this Convertible Note as of the date first above written.

	DEBTOR:	HOLDER:
	Neuropathix,
    Inc.,	[________________________],
	a
    Delaware corporation	a
    [_______________________]
	By:
    __________________	By:
    _______________________
	Dean
    Petkanas, CEO	[__________________________]

 

    	 	2	 

     

    

 

 ATTACHMENT
1

CONVERSION
NOTICE

	Neuropathix,
    Inc.	 	Date:
                                            __________________	 

Attn:
Dean Petkanas, CEO

CONVERSION
NOTICE

Holder
hereby gives notice to Neuropathix, Inc., a Delaware corporation (the “Company”), pursuant to that certain Convertible Promissory
Note, face value $50,000 dated March 21, 2022, made by the Company in favor of Holder (the “Note”), that Holder elects to
convert the portion of the Note balance set forth below into fully paid and non-assessable shares of the Company’s regular common
stock as of the date of conversion specified below. Said conversion shall be based on the Conversion Price set forth below.

		A.	Date
                                            of conversion: __________________________

		B.	Conversion
                                            Amount: _________________________

		C.	Conversion
                                            Price: ____________________________

		D.	Conversion
                                            Shares: ___________________________ (B divided by C)

		E.	Remaining
                                            Outstanding Balance of Note: $____________________ including interest accrued thereon of
                                            $_____________ as of the date of this Conversion Notice.

 

Sincerely,

 

    	 	3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]